Saturday, 17 October 2026European Markets

BELIEVE Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with believe (blv.pa) rising 18.39% to €14.68 on tuesday while cac 40 slid 0.84% to €7,625.31.

believe's last close was €12.40, 2.82% below its 52-week high of €12.76.

about believe

believe s.a. provides music distribution and marketing services for artists and labels worldwide. the company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. it also provides brand partnership, video, synchronization, music publishing and additional services. believe s.a. was incorporated in 2005 and is headquartered in paris, france.

earnings per share

as for profitability, believe has a trailing twelve months eps of €-0.22.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.27%.

sales growth

believe's sales growth is 32.3% for the ongoing quarter and 14.3% for the next.

moving average

believe's worth is way above its 50-day moving average of €10.55 and way higher than its 200-day moving average of €10.24.

more news about believe (blv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com